Immunotherapy for Oncological Cancer: ASCO Focus

ASCO’s (American Society of Clinical Oncology) annual meeting is one of the largest educational and scientific oncology events in the world. Recently ASCO has organized a five day event from 3rd, June to 7th June 2016 held in Chicago, United States, in the presences of Vice President, Joe Biden that provided a platform for physicians and scientists to present their research results to a global audience of oncology professionals. This annual meeting of ASCO was attended by more than 40,000 attendees and approximately 3,000 abstracts were submitted internationally from over 80 countries.

Dr. Jamal KhanA landmark development in the field of oncology cancer has already taken its place in India by Dr. Jamal A. Khan since 2006. Dr. Jamal’s DENVAX is a Dendritic Cell (DC)-based cancer immunotherapy that prevents to the recurrence of cancer after surgery, chemotherapy or radiation because the immune system will need to recognize and attack a smaller number of cancer cells, which was the main theme of the ASCO event.

Speaking about the ASCO event, Dr. Jamal A. Khan, renowned as a pioneer in Cancer Immunotherapy in India and the Director, DENVAX shared, “In the area of neoplasm, oncology is the best therapy till date on which ASCO is consistently focused and uplifting DC based immunotherapy for various types of cancers (advanced triple-negative breast cancer, advanced lung adenocarcinoma, advanced pancreatic cancer and hepatocellular carcinoma etc.) treatment.

The Standard approaches to various cancer treatments involve surgery, chemotherapy and radiation, but recurrent/advanced/metastatic cancers often develop resistance to standard chemotherapies along with second and third line drugs, which are also responsible for considerable morbidity and death. So, there is an urgent need for alternative approaches based on more specific targeted therapies and immunotherapy to treat the patients with recurrent/advanced/metastatic cancers”, added by Dr. Khan.

Dendritic cellDr. Jamal’s Denvax is a reconcilable treatment so it can be given alone or in the combination with other treatment modalities. Dendritic cell therapy comes under the heading of Biological Therapy of Cancer, the fourth modality of cancer treatment after surgery, radiation and chemotherapy. The components of DENVAX include patient's own mononuclear cells manipulated into cancer-fighting Dendritic cells; there is no graft versus host reaction or acute or delayed-type hypersensitivity.

About DENVAX: DENVAX is a dendritic cell based cancer immunotherapy. Dendritic cells (DC) therapy delays cancer progression and improves patient survival. At ICT, DENVAX has treated large number cancer patients with M1 (metastatic) disease who are leading a recurrence-free quality life for many months to years. DENVAX has its laboratory in Noida and has multiple clinics in India i.e. Delhi, Mumbai, Ahmadabad, Kolkata and it has recently established its new clinic in Dubai.

About ASCO: ASCO (American Society of Clinical Oncology) founded in 1964, is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO provides an exemplary education and resources to support oncology practices and promote the delivery of high-quality, high-value cancer care. The Conquer Cancer Foundation (CCF) was also founded by the foremost cancer doctors of the ASCO.

Orion PR & Digital Pvt. Ltd.
Ramakant Mathur, Senior Campaign Executive
806A, 58 Sahyog Building, Nehru Place, Delhi 110019, +91 22 61676868

Image: Artistic rendering of the surface of a human dendritic cell illustrating sheet-like processes that fold back onto the membrane surface. When exposed to HIV, these sheets entrap viruses in the vicinity and focus them to contact zones with T-cells targeted for infection. These studies were carried out using ion abrasion scanning electron microscopy, a new technology we have been developing and applying for 3D cellular imaging. Categories: Research in NIH Labs and Clinics Type: Color, Diagram Source: National Cancer Institute (NCI) Creator: Don Bliss, Sriram Subramaniam Date Created: Unknown Date Added: 5/24/2012. Source/Author: National Institutes of Health (NIH). Access the original Image information here:


Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Oncology, Press Releases, Press Releases Featured 2 and tagged , , . Volume: .

Post a Comment

You must be logged in to post a comment.